Compare DOX & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOX | XENE |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 1998 | 2014 |
| Metric | DOX | XENE |
|---|---|---|
| Price | $62.60 | $60.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $92.33 | $68.55 |
| AVG Volume (30 Days) | ★ 1.1M | 645.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $3.76 | $2,496.48 |
| P/E Ratio | $13.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $49.74 | $35.60 |
| 52 Week High | $86.01 | $72.66 |
| Indicator | DOX | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 66.59 | 42.23 |
| Support Level | $59.40 | $52.40 |
| Resistance Level | $63.92 | $62.91 |
| Average True Range (ATR) | 1.45 | 2.28 |
| MACD | 0.19 | -0.30 |
| Stochastic Oscillator | 73.33 | 9.03 |
Amdocs Ltd is a provider of software and services to communications, entertainment, and media service providers. The Company operates in a single segment and designs, develops, markets, supports, implements, and operates open and modular cloud offerings. Its portfolio includes solutions across digital business systems and legacy business and operational support systems, supporting multiple lines of business such as wireless, broadband, cable, fiber, satellite, and digital services. The Company leverages artificial intelligence to support digital transformation, cloud adoption, and intelligent network automation. Geographically, it derives a majority of its revenue from North America and also operates in Europe and the rest of the world.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.